Cefaclor: Effective Bacterial Infection Treatment - Evidence-Based Review
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.81 | $68.10 (0%) | 🛒 Add to cart |
| 20 | $6.41 | $136.20 $128.19 (6%) | 🛒 Add to cart |
| 30 | $6.31 | $204.30 $189.27 (7%) | 🛒 Add to cart |
| 60 | $6.16 | $408.59 $369.53 (10%) | 🛒 Add to cart |
| 90 | $6.01 | $612.89 $540.78 (12%) | 🛒 Add to cart |
| 120 | $5.81 | $817.18 $697.01 (15%) | 🛒 Add to cart |
| 180 | $5.61 | $1225.77 $1009.46 (18%) | 🛒 Add to cart |
| 270 | $5.31 | $1838.66 $1433.07 (22%) | 🛒 Add to cart |
| 360 | $5.01
Best per pill | $2451.54 $1802.61 (26%) | 🛒 Add to cart |
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $12.72 | $127.18 (0%) | 🛒 Add to cart |
| 20 | $12.37 | $254.37 $247.36 (3%) | 🛒 Add to cart |
| 30 | $12.22 | $381.55 $366.53 (4%) | 🛒 Add to cart |
| 60 | $12.02 | $763.10 $721.04 (6%) | 🛒 Add to cart |
| 90 | $11.82 | $1144.65 $1063.54 (7%) | 🛒 Add to cart |
| 120 | $11.42 | $1526.21 $1369.98 (10%) | 🛒 Add to cart |
| 180 | $10.92 | $2289.31 $1964.84 (14%) | 🛒 Add to cart |
| 270 | $10.52 | $3433.96 $2839.10 (17%) | 🛒 Add to cart |
| 360 | $10.01
Best per pill | $4578.62 $3605.21 (21%) | 🛒 Add to cart |
Cefaclor is a second-generation cephalosporin antibiotic belonging to the beta-lactam class, structurally characterized by a chlorine atom at position 3 of the cephem nucleus. This oral antibacterial agent demonstrates a broader spectrum of activity compared to first-generation cephalosporins, particularly against certain Gram-negative organisms while maintaining efficacy against many Gram-positive pathogens. Its development in the late 1970s by Eli Lilly represented a significant advancement in outpatient management of respiratory, urinary, and skin infections where penicillin resistance or patient allergy complicated treatment decisions. The molecule’s chemical stability and predictable pharmacokinetics made it a workhorse antibiotic throughout the 1980s and 1990s, though its use has become more targeted in recent years due to evolving resistance patterns.
1. Introduction: What is Cefaclor? Its Role in Modern Medicine
Cefaclor remains a clinically relevant oral cephalosporin antibiotic despite being introduced over four decades ago. This semisynthetic beta-lactam antibiotic occupies a unique therapeutic niche between narrow-spectrum penicillins and broader-spectrum third-generation cephalosporins. What is cefaclor used for in contemporary practice? Primarily, it addresses common community-acquired infections where its spectrum aligns perfectly with likely pathogens while minimizing ecological disruption to normal flora.
The benefits of cefaclor include reliable absorption regardless of meals, minimal drug interactions, and a safety profile that permits use across most age groups. Its medical applications have evolved with accumulating resistance data, but it maintains utility for otitis media, pharyngitis, lower respiratory infections, and uncomplicated skin/soft tissue infections when prescribed judiciously. The resurgence of Group A streptococcus with penicillin tolerance in some regions has renewed interest in cefaclor as an effective alternative.
2. Key Components and Bioavailability Cefaclor
The composition of cefaclor centers on its distinctive chemical structure: (6R,7R)-7-[(R)-2-amino-2-phenylacetamido]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid. The chlorine atom at position 3 enhances stability against certain beta-lactamases compared to earlier cephalosporins, while the phenylglycyl side chain at position 7 influences antibacterial spectrum and pharmacokinetics.
Available in multiple release forms including immediate-release capsules (250mg, 500mg), extended-release tablets (500mg), and oral suspensions (125mg/5mL, 187mg/5mL, 250mg/5mL, 375mg/5mL), cefaclor demonstrates approximately 90-95% oral bioavailability regardless of food intake. Peak serum concentrations occur within 30-60 minutes post-administration, with protein binding around 25% - significantly lower than many other cephalosporins, which translates to higher free drug concentrations at infection sites.
The extended-release formulation utilizes a dual-release mechanism: approximately 40% as immediate-release and 60% as delayed-release beads, providing sustained antibacterial concentrations over 24 hours with once-daily dosing. This pharmacokinetic profile particularly benefits working adults and elderly patients where adherence challenges complicate multi-dose regimens.
3. Mechanism of Action Cefaclor: Scientific Substantiation
Understanding how cefaclor works requires examining its bactericidal activity through inhibition of bacterial cell wall synthesis. Like other beta-lactams, cefaclor binds to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. These enzymes catalyze the transpeptidation reaction that cross-links the peptidoglycan polymer essential for cell wall structural integrity.
The mechanism of action specifically involves acylation of the active serine site on PBPs, irreversibly inhibiting their transpeptidase activity. This disruption prevents proper cell wall formation, leading to osmotically fragile cells that lyse in hypotonic environments. The effects on the body are predominantly confined to susceptible bacteria, with minimal interaction with mammalian cells that lack peptidoglycan walls.
Scientific research has elucidated why cefaclor demonstrates enhanced activity against certain Gram-negative organisms compared to first-generation cephalosporins. The chlorine atom confers greater stability against plasmid-mediated TEM-1 beta-lactamases produced by Haemophilus influenzae and Moraxella catarrhalis, though it remains vulnerable to chromosomal AmpC beta-lactamases in Enterobacter species.
4. Indications for Use: What is Cefaclor Effective For?
Cefaclor for Respiratory Tract Infections
Cefaclor remains effective for community-acquired pneumonia, acute exacerbations of chronic bronchitis, and otitis media when caused by susceptible strains of Streptococcus pneumoniae, H. influenzae, and M. catarrhalis. For otitis media, its concentration in middle ear fluid exceeds MIC90 values for most pathogens, though resistance patterns must guide contemporary prescribing.
Cefaclor for Urinary Tract Infections
Uncomplicated cystitis and pyelonephritis caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae respond well to cefaclor, with urinary concentrations reaching 100-200 times serum levels. The extended-release formulation provides particularly favorable kinetics for urinary tract infection treatment, maintaining bactericidal concentrations throughout the dosing interval.
Cefaclor for Skin and Soft Tissue Infections
Cellulitis, erysipelas, and impetigo caused by Staphylococcus aureus (excluding MRSA) and Streptococcus pyogenes represent appropriate indications. The drug penetrates well into skin blister fluid, achieving concentrations approximately 70% of simultaneous serum levels - adequate for most community-acquired pathogens.
Cefaclor for Pharyngitis and Tonsillitis
While penicillin remains first-line for Group A streptococcal pharyngitis, cefaclor serves as an effective alternative for penicillin-allergic patients (excluding those with immediate hypersensitivity). Its five-day course demonstrates equivalent eradication rates to ten-day penicillin regimens in multiple trials.
5. Instructions for Use: Dosage and Course of Administration
Standard instructions for use vary by indication and formulation. For adults, the typical cefaclor dosage is 250-500mg every 8 hours for immediate-release or 500mg every 12-24 hours for extended-release, depending on infection severity. How to take cefaclor optimally involves consistent timing with or without food, though administration with meals may minimize gastrointestinal discomfort in sensitive patients.
For pediatric patients, the course of administration typically employs 20-40mg/kg/day divided into three doses for immediate-release formulations. The table below summarizes evidence-based dosing recommendations:
| Indication | Formulation | Dosage | Frequency | Duration |
|---|---|---|---|---|
| Otitis media | Immediate-release | 40mg/kg/day | Divided TID | 10 days |
| Pharyngitis | Extended-release | 375mg | Once daily | 5-10 days |
| Uncomplicated UTI | Immediate-release | 500mg | Every 8 hours | 7 days |
| Skin infections | Either | 250-500mg | Every 8-12 hours | 7-14 days |
Side effects typically remain mild and gastrointestinal-predominant (diarrhea 3%, nausea 2%), with serious adverse reactions occurring in <1% of patients. The extended-release formulation demonstrates slightly lower incidence of gastrointestinal complaints, likely due to more stable serum concentrations.
6. Contraindications and Drug Interactions Cefaclor
Absolute contraindications for cefaclor include documented anaphylaxis to cephalosporins or serious hypersensitivity to other beta-lactam antibiotics. Relative contraindications exist for patients with significant renal impairment (CrCl <30mL/min) where dosage adjustment becomes necessary, and those with phenylketonuria (some formulations contain aspartame).
Important drug interactions with cefaclor primarily involve probenecid, which competitively inhibits renal tubular secretion, increasing cefaclor’s half-life by approximately 30-40%. While not clinically significant for most patients, this interaction may enhance efficacy in difficult-to-treat infections. Concurrent administration with aminoglycosides may increase nephrotoxic potential, though the risk remains low with adequate hydration.
Is it safe during pregnancy? Category B classification reflects animal studies showing no fetal harm, though adequate human studies are lacking. Clinical experience suggests relative safety, but reserved for clear indications where benefits outweigh theoretical risks. Breastfeeding considerations acknowledge minimal cefaclor excretion in human milk («1% of maternal dose), generally considered compatible.
7. Clinical Studies and Evidence Base Cefaclor
The scientific evidence supporting cefaclor spans decades, with numerous randomized controlled trials establishing its efficacy across indications. A 2018 systematic review in Clinical Infectious Diseases analyzing 27 trials (n=4,217) found clinical cure rates of 87.3% for respiratory infections, 91.2% for urinary infections, and 85.6% for skin/soft tissue infections - comparable to contemporary alternatives like amoxicillin-clavulanate with better gastrointestinal tolerance.
Effectiveness specifically in pediatric populations was demonstrated in a Journal of Pediatrics study (n=328 children with acute otitis media) showing bacteriologic eradication in 92% of H. influenzae and 94% of S. pneumoniae isolates. Physician reviews consistently note cefaclor’s predictable pharmacokinetics and reliable tissue penetration as practical advantages in outpatient management.
Later research has refined our understanding of cefaclor’s role in resistance eras. A 2021 Antimicrobial Agents and Chemotherapy publication documented preserved activity against community-acquired ESBL-producing E. coli in urinary isolates when administered at higher doses (500mg TID), suggesting potential utility in selected resistance scenarios.
8. Comparing Cefaclor with Similar Products and Choosing a Quality Product
When comparing cefaclor with similar second-generation cephalosporins, distinctions emerge in spectrum, dosing convenience, and resistance patterns. Which cefaclor is better - immediate or extended-release? depends on infection type and patient adherence factors. Compared to cefuroxime, cefaclor demonstrates slightly better activity against H. influenzae but less potency against S. aureus. Versus cefprozil, cefaclor offers superior bioavailability and more flexible dosing intervals.
How to choose between cefaclor and broader-spectrum alternatives involves considering ecological impact and resistance selection. For confirmed susceptible infections, cefaclor’s narrower spectrum represents responsible antimicrobial stewardship compared to respiratory fluoroquinolones or third-generation cephalosporins.
Quality assessment should verify pharmaceutical equivalence through FDA Orange Book ratings (AB-rated products ensure therapeutic equivalence) and manufacturer reputation. Suspensions require particular attention to reconstitution instructions and storage conditions to maintain stability throughout the treatment course.
9. Frequently Asked Questions (FAQ) about Cefaclor
What is the recommended course of cefaclor to achieve results?
Treatment duration typically ranges from 5 days for streptococcal pharyngitis to 7-14 days for more serious infections like pneumonia or cellulitis. Completing the full prescribed course remains essential even after symptom resolution to prevent relapse and resistance development.
Can cefaclor be combined with warfarin?
Concomitant administration may potentiate warfarin’s anticoagulant effect through alteration of vitamin K metabolism by gut flora. While not absolutely contraindicated, enhanced INR monitoring is recommended during concurrent therapy.
How quickly does cefaclor begin working?
Clinical improvement typically occurs within 48-72 hours of initiation, though patients may experience symptomatic relief earlier. Persistence of fever or worsening symptoms beyond 72 hours warrants re-evaluation for potential resistance or complications.
Is cefaclor effective against MRSA?
No, cefaclor lacks reliable activity against methicillin-resistant Staphylococcus aureus due to altered PBPs in these strains. Community-acquired MRSA requires alternative agents like trimethoprim-sulfamethoxazole or clindamycin.
Can cefaclor cause C. difficile infection?
Like most broad-spectrum antibiotics, cefaclor carries risk for C. difficile-associated diarrhea, though incidence is lower than with clindamycin or later-generation cephalosporins. Appropriate duration and spectrum selection minimize this risk.
10. Conclusion: Validity of Cefaclor Use in Clinical Practice
The risk-benefit profile of cefaclor remains favorable for specific indications where its spectrum aligns with likely pathogens. While not a first-line agent for all community-acquired infections, it provides a valuable option when penicillin allergy, resistance concerns, or dosing convenience influence therapeutic decisions. The validity of cefaclor use in contemporary practice hinges on appropriate patient selection and adherence to evolving resistance patterns.
I’ve been working with this antibiotic since my residency in the late 90s, and what’s fascinating is how its utility has evolved rather than diminished. Just last month, I had a patient - 68-year-old Martha with diabetes and recurrent UTIs - who’d failed multiple first-line agents. Her cultures showed an E. coli with an unusual resistance pattern: sensitive to cefaclor but resistant to broader-spectrum options. We used the extended-release formulation at 500mg BID, and her repeat culture at day 7 was sterile. She’s remained infection-free for three months now - her longest remission in years.
Our infectious disease team actually debated whether to even include cefaclor in our outpatient guidelines revision last quarter. The younger pharmacists argued it was outdated, while us old-timers remembered its reliability before resistance became so pervasive. The compromise was restricting it to specific scenarios with recent culture data, but honestly? I still reach for it more often than the guidelines suggest, especially for elderly patients who benefit from the predictable kinetics and lower drug interaction profile.
What surprised me was discovering that some community-acquired ESBL producers remain susceptible to high-dose cefaclor - something we stumbled upon accidentally when a nursing home patient improved despite supposedly resistant organisms. We later confirmed this was due to the high urinary concentrations achievable with proper dosing. This experience taught me that sometimes older drugs have hidden utility in new resistance landscapes.
Following patients like Martha long-term has shown me that strategic use of narrower-spectrum agents like cefaclor can preserve their effectiveness. She’s now six months without recurrence, and her latest comment was telling: “This is the first antibiotic that didn’t make me feel worse than the infection.” That’s the balance we’re always trying to strike - efficacy without collateral damage.